TG Therapeutics launches first clinical trial in multiple sclerosis for TG-1101
TG Therapeutics announced the opening of its Phase 2 clinical study of TG-1101 (ublituximab), the Company's glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing remitting multiple sclerosis, a chronic demyelinating disease of the central nervous system. May 03, 2016